PSMA7

Across TCGA pan-cancer cohorts, PSMA7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMA7 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMA7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMA7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where PSMA7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.587	0.872	.002	23	view →
HNSC	DFS	Tertile	IV	1.000	0.891	.033	6	view →
LSCC	DFS	Tertile	All	1.000	0.660	.018	4	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	3	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMA7–LUAD (OS)

Open the LUAD breakdown →